Advertisement

Tumor Biology

, Volume 33, Issue 5, pp 1573–1580 | Cite as

The prognostic significance of tumor-associated stroma in invasive breast carcinoma

  • Soomin Ahn
  • Junhun Cho
  • Jiyoun Sung
  • Jeong Eon Lee
  • Seok Jin Nam
  • Kyoung-Mee Kim
  • Eun Yoon Cho
Research Article

Abstract

Fibroblasts in the stromal component of a tumor may influence tumor progression in various organs. The prognostic significance of tumor-infiltrating lymphocytes is also frequently reported. However, the prognostic significance of the stromal component in breast cancers, particularly those of high grade, has not been established. In this study, we analyzed surgically resected specimens from 545 patients with breast carcinoma, including 193 high-grade tumors, for tumor–stroma ratio, dominant stroma type [collagen (C), fibroblast (F), or lymphocyte (L) dominant type], and central fibrosis on hematoxylin–eosin-stained histological sections. We correlated these features with clinical prognosis. Among the 533 specimens examined, 127 (23.3 %) were of C type, 292 (53.6 %) of F type, and 114 (20.9 %) of L type. Central fibrosis was found in 99 tumors (18 %). The dominant stroma type was a significant prognostic factor on univariate and multivariate analyses, together with T classification, nodal status, and Bloom–Richardson grade. Tumor–stroma ratio and central fibrosis did not predict survival on multivariate analysis. Even in high-grade tumors, relapse-free intervals differed significantly according to dominant stroma type. Thus, conventional hematoxylin–eosin-stained tumor slides may contain more prognostic information than previously thought; in particular, the dominant stroma type in invasive breast cancer may potentially be used to predict outcome.

Keywords

Invasive breast cancer Tumor stroma Disease-free survival Multivariate analysis 

Abbreviations

DFS

Disease-free survival

ER

Estrogen receptor

PR

Progesterone receptor

DFI

Disease-free interval

OS

Overall survival

Notes

Acknowledgments

This study was supported by a Samsung Biomedical Research Institute grant, #SBRI C-B0-319-2.

References

  1. 1.
    DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–18.CrossRefPubMedGoogle Scholar
  2. 2.
    de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA, Mesker WE. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat. 2011;125:687–96.CrossRefPubMedGoogle Scholar
  3. 3.
    Saito RA, Micke P, Paulsson J, Augsten M, Pena C, Jonsson P, Botling J, Edlund K, Johansson L, Carlsson P, Jirstrom K, Miyazono K, Ostman A. Forkhead box f1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res. 2010;70:2644–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007;13:2082–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang C, Fu L, Fu J, Hu L, Yang H, Rong TH, Li Y, Liu H, Fu SB, Zeng YX, Guan XY. Fibroblast growth factor receptor 2-positive fibroblasts provide a suitable microenvironment for tumor development and progression in esophageal carcinoma. Clin Cancer Res. 2009;15:4017–27.CrossRefPubMedGoogle Scholar
  6. 6.
    West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, Montgomery K, Zhu S, Patel R, Hernandez-Boussard T, Goldblum JR, Brown PO, van de Vijver M, van de Rijn M. Determination of stromal signatures in breast carcinoma. PLoS Biol. 2005;3:e187.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004;2:E7.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–27.CrossRefPubMedGoogle Scholar
  9. 9.
    De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200:429–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Hasebe T, Sasaki S, Imoto S, Ochiai A. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol. 2001;14:325–37.CrossRefPubMedGoogle Scholar
  11. 11.
    Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–48.CrossRefPubMedGoogle Scholar
  12. 12.
    Hasebe T, Iwasaki M, Akashi-Tanaka S, Hojo T, Shibata T, Sasajima Y, Kinoshita T, Tsuda H. Atypical tumor-stromal fibroblasts in invasive ductal carcinoma of the breast. Am J Surg Pathol. 2011;35:325–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Liu F, Lang R, Zhao J, Zhang X, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130:645–55.CrossRefPubMedGoogle Scholar
  14. 14.
    Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, Rochaix P, Girard JP. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71:5678–87.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee AH, Gillett CE, Ryder K, Fentiman IS, Miles DW, Millis RR. Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology. 2006;48:692–701.CrossRefPubMedGoogle Scholar
  16. 16.
    Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat. 2003;81:137–47.CrossRefPubMedGoogle Scholar
  17. 17.
    Barsky SH, Gopalakrishna R. Increased invasion and spontaneous metastasis of bl6 melanoma with inhibition of the desmoplastic response in C57 BL/6 mice. Cancer Res. 1987;47:1663–7.PubMedGoogle Scholar
  18. 18.
    Ueno H, Jones A, Jass JR, Talbot IC. Clinicopathological significance of the ‘keloid-like’ collagen and myxoid stroma in advanced rectal cancer. Histopathology. 2002;40:327–34.CrossRefPubMedGoogle Scholar
  19. 19.
    Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, Ochiai A. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol. 2002;15:502–16.CrossRefPubMedGoogle Scholar
  20. 20.
    Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y, Yamamoto H, Mukai K. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat. 1998;49:195–208.CrossRefPubMedGoogle Scholar
  21. 21.
    Baak JP, Colpaert CG, van Diest PJ, Janssen E, van Diermen B, Albernaz E, Vermeulen PB, Van Marck EA. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer. 2005;41:2093–101.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Soomin Ahn
    • 1
  • Junhun Cho
    • 1
  • Jiyoun Sung
    • 1
  • Jeong Eon Lee
    • 2
  • Seok Jin Nam
    • 2
  • Kyoung-Mee Kim
    • 1
  • Eun Yoon Cho
    • 1
  1. 1.Department of Pathology, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  2. 2.Department of Surgery, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations